Each uncoated bilayered tablet contains Glimepiride 1 mg + Pioglitazone 15 mg + Metformin Hydrochloride SR 1000 mg.

Tripride 1 Forte Tablets combine Glimepiride (sulfonylurea), Pioglitazone (thiazolidinedione), and Sustained-Release Metformin (biguanide) to provide comprehensive glycaemic control in adults with type 2 diabetes mellitus. Glimepiride stimulates insulin secretion from pancreatic beta cells, Pioglitazone improves insulin sensitivity by activating PPAR-γ receptors, and Metformin reduces hepatic glucose production while enhancing peripheral glucose uptake. The triple-drug combination targets multiple defects in glucose metabolism and is intended for patients who do not achieve adequate glycaemic control with monotherapy or dual therapy.

Tripride 1 Forte Tablets are indicated for the treatment of type 2 diabetes mellitus (T2DM) in patients whose glycaemic targets are not achieved with diet, exercise, monotherapy, or dual antidiabetic therapy.

Glimepiride lowers blood glucose primarily by stimulating insulin release from functioning pancreatic beta cells. Pioglitazone selectively activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in muscle, adipose tissue, and the liver by regulating the expression of insulin-responsive genes involved in glucose and lipid metabolism. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Together, these complementary mechanisms provide effective control of fasting and postprandial blood glucose.

The recommended initial dosage is one tablet orally once daily, or as directed by the physician.

Tripride 1 Forte Tablets are contraindicated in patients with renal impairment, metabolic acidosis including diabetic ketoacidosis, and known hypersensitivity to Glimepiride, Pioglitazone, Metformin, or any component of the formulation.